• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感染人乳头瘤病毒16型的女性体内体液免疫和细胞介导免疫反应的时间进程

Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

作者信息

Nakagawa Mayumi, Viscidi Raphael, Deshmukh Ian, Costa Maria Da, Palefsky Joel M, Farhat Sepideh, Moscicki Anna-Barbara

机构信息

Departments of Laboratory Medicine, Schools of Medicine and Dentistry, University of California at San Francisco, San Francisco, California 94143-0134, USA.

出版信息

Clin Diagn Lab Immunol. 2002 Jul;9(4):877-82. doi: 10.1128/cdli.9.4.877-882.2002.

DOI:10.1128/cdli.9.4.877-882.2002
PMID:12093689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC120038/
Abstract

The time course of cell-mediated and humoral immune responses was elucidated in eight women with human papillomavirus type 16 (HPV-16) infection by performing serial HPV-16 E6 and E7 cytotoxic T-lymphocyte (CTL) assays and HPV-16 virus-like particle (VLP) antibody analyses. Four subjects had a single incident of HPV-16 DNA detection, and four subjects had two periods of HPV-16 DNA detection. In two of the women in the latter group, the second episode of HPV-16 detection occurred in the presence of high titers of HPV-16 VLP antibody, bringing into question the protective role of humoral immunity in preventing repeated infection. However, all four subjects rapidly became HPV-16 DNA negative following the second detection of HPV-16 DNA, suggesting the presence of immunological memory. In addition, one subject rapidly became negative for HPV-16 DNA despite having no evidence of CTL or VLP antibody response prior to the second HPV-16 DNA detection, suggesting the presence of immunological responses at an undetectable level. Overall, seven of eight subjects (88%) had detectable HPV-16 E6 and/or E7 CTL responses and seven of eight women (88%) had detectable HPV-16 VLP antibody responses.

摘要

通过进行系列人乳头瘤病毒16型(HPV - 16)E6和E7细胞毒性T淋巴细胞(CTL)检测以及HPV - 16病毒样颗粒(VLP)抗体分析,阐明了8名感染HPV - 16的女性细胞介导免疫反应和体液免疫反应的时间进程。4名受试者有单次HPV - 16 DNA检测事件,4名受试者有两个阶段的HPV - 16 DNA检测。在后一组中的2名女性中,第二次HPV - 16检测事件发生在高滴度HPV - 16 VLP抗体存在的情况下,这使人质疑体液免疫在预防重复感染中的保护作用。然而,所有4名受试者在第二次检测到HPV - 16 DNA后迅速变为HPV - 16 DNA阴性,提示存在免疫记忆。此外,1名受试者在第二次HPV - 16 DNA检测前虽无CTL或VLP抗体反应的证据,但HPV - 16 DNA迅速变为阴性,提示存在无法检测到水平的免疫反应。总体而言,8名受试者中有7名(88%)有可检测到的HPV - 16 E6和/或E7 CTL反应,8名女性中有7名(88%)有可检测到的HPV - 16 VLP抗体反应。

相似文献

1
Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.感染人乳头瘤病毒16型的女性体内体液免疫和细胞介导免疫反应的时间进程
Clin Diagn Lab Immunol. 2002 Jul;9(4):877-82. doi: 10.1128/cdli.9.4.877-882.2002.
2
Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens.
J Infect Dis. 2000 Aug;182(2):595-8. doi: 10.1086/315706. Epub 2000 Jul 28.
3
Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.来自巴西患有浸润性宫颈癌女性的人乳头瘤病毒16型蛋白血清抗体
Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):935-40.
4
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.接种编码人乳头瘤病毒16/18癌蛋白的痘苗病毒的外阴上皮内瘤变女性的免疫和临床反应。
Cancer Res. 2003 Sep 15;63(18):6032-41.
5
Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.E7和CpG-寡脱氧核苷酸对于抵抗人乳头瘤病毒16型(E6/E7)永生化肿瘤细胞攻击的保护性免疫均是必需的:CD4+和CD8+ T细胞参与保护作用。
Cancer Res. 2002 Dec 15;62(24):7234-40.
6
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.健康人群中频繁出现16型人乳头瘤病毒E6特异性记忆性辅助性T细胞,证明曾接触过该病毒。
Cancer Res. 2003 Feb 1;63(3):636-41.
7
Human papillomavirus seropositivity and risks of head and neck cancer.人乳头瘤病毒血清阳性与头颈癌风险
Int J Cancer. 2007 Feb 15;120(4):825-32. doi: 10.1002/ijc.22330.
8
Detection of human papillomavirus type 16 DNA and of antibodies to human papillomavirus type 16 proteins in children.儿童中16型人乳头瘤病毒DNA及16型人乳头瘤病毒蛋白抗体的检测
Intervirology. 1997;40(4):232-7. doi: 10.1159/000150552.
9
Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection.对人乳头瘤病毒16型L1E7嵌合病毒样颗粒的免疫反应:细胞毒性T细胞的诱导及特异性肿瘤保护作用
Int J Cancer. 1999 Jun 11;81(6):881-8. doi: 10.1002/(sici)1097-0215(19990611)81:6<881::aid-ijc8>3.0.co;2-t.
10
Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific.对16型人乳头瘤病毒(HPV)E7肽的细胞介导免疫反应取决于感染子宫颈的HPV类型,而血清学反应则不具有型特异性。
J Gen Virol. 1994 Sep;75 ( Pt 9):2277-84. doi: 10.1099/0022-1317-75-9-2277.

引用本文的文献

1
The Immune Response Generated against HPV Infection in Men and Its Implications in the Diagnosis of Cancer.男性针对人乳头瘤病毒(HPV)感染产生的免疫反应及其在癌症诊断中的意义。
Microorganisms. 2023 Jun 18;11(6):1609. doi: 10.3390/microorganisms11061609.
2
Vaccination Against Cervical Cancer: Hopes and Realities.宫颈癌疫苗接种:希望与现实
Am J Cancer (Auckl). 2005 Jul;4(4):207-219. doi: 10.2165/00024669-200504040-00001.
3
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.针对 HPV16/18 的免疫疗法可产生强烈的 TH1 和细胞毒性细胞免疫应答。
Sci Transl Med. 2012 Oct 10;4(155):155ra138. doi: 10.1126/scitranslmed.3004414.
4
A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.一种新型 HPV 16 L1 嵌合病毒样颗粒,包含 E6 和 E7 血清反应性表位,可高度特异性检测 CIN 1 和 HPV-16 感染患者的抗体。
Virol J. 2011 Feb 9;8:59. doi: 10.1186/1743-422X-8-59.
5
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.人乳头瘤病毒诱导病变免疫治疗策略的最新进展
Int J Cancer. 2008 Jan 15;122(2):247-59. doi: 10.1002/ijc.23252.
6
Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara.用由博德特氏菌腺苷酸环化酶和改良安卡拉痘苗病毒递送的E7蛋白对HPV16诱导的肿瘤进行初免/加强免疫治疗。
Cancer Immunol Immunother. 2006 Jan;55(1):39-46. doi: 10.1007/s00262-005-0700-7. Epub 2005 Oct 27.

本文引用的文献

1
Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.年轻女性发生人乳头瘤病毒感染及低级别鳞状上皮内病变的风险
JAMA. 2001 Jun 20;285(23):2995-3002. doi: 10.1001/jama.285.23.2995.
2
HPV vaccine moves into late stage trials.人乳头瘤病毒疫苗进入后期试验阶段。
Nat Med. 2001 Apr;7(4):388. doi: 10.1038/86408.
3
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.人乳头瘤病毒16型L1病毒样颗粒疫苗在成年志愿者中的安全性和免疫原性试验。
J Natl Cancer Inst. 2001 Feb 21;93(4):284-92. doi: 10.1093/jnci/93.4.284.
4
NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.非高危型人乳头瘤病毒16型病毒样颗粒疫苗可诱导产生能中和不同HPV16变体的人类抗体。
Virology. 2001 Jan 5;279(1):361-9. doi: 10.1006/viro.2000.0702.
5
Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens.
J Infect Dis. 2000 Aug;182(2):595-8. doi: 10.1086/315706. Epub 2000 Jul 28.
6
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.初次感染后人乳头瘤病毒16型、18型和6型衣壳抗体反应的比较。
J Infect Dis. 2000 Jun;181(6):1911-9. doi: 10.1086/315498. Epub 2000 May 31.
7
Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae.从酿酒酵母中纯化重组人乳头瘤病毒11型主要衣壳蛋白L1的病毒样颗粒
Protein Expr Purif. 1999 Dec;17(3):477-84. doi: 10.1006/prep.1999.1155.
8
Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis.
J Gen Virol. 1999 Nov;80 ( Pt 11):2931-2936. doi: 10.1099/0022-1317-80-11-2931.
9
Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.来自巴西患有浸润性宫颈癌女性的人乳头瘤病毒16型蛋白血清抗体
Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):935-40.
10
Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions.一项关于宫颈鳞状上皮内病变的病例对照研究中对人乳头瘤病毒16、18、31和45型病毒样颗粒的血清反应性
J Infect Dis. 1999 Nov;180(5):1424-8. doi: 10.1086/315055.